Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 11/2016

01-11-2016 | Original Article

Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity

Authors: C.-B. Yeh, S.-J. Weng, K.-W. Chang, J. Y.-H. Chan, S.-M. Huang, T.-H. Chu, N.-K. Wei, H.-S. Ma, J.-T. Cheng, K.-H. Ma, T.-H. Chen, J.-F. Shyu

Published in: Osteoporosis International | Issue 11/2016

Login to get access

Abstract

Summary

Calcitonin may relieve pain by modulating central serotonin activity. Calcitonin partly reversed the hypersensitivity to pain induced by ovariectomy. This suggests that the anti-nociceptive effects of calcitonin in the treatment of osteoporosis may be mediated by alterations in neural serotonin transporter (SERT) activity.

Introduction

This study used a rat model of osteoporosis to evaluate the role of the cerebral serotonin system in the anti-nociceptive effect of calcitonin, a drug used to treat post-menopausal osteoporosis.

Methods

Osteoporosis was induced in rats by ovariectomy (OVX). Rats were then randomized to the following four groups: sham operation, OVX, OVX plus calcitonin, or OVX plus alendronate.

Results

OVX led to alterations in bone micro-architecture; alendronate strongly reversed this effect, and calcitonin moderately reversed this effect. OVX increased hyperalgesia (determined as the time for hind paw withdrawal from a heat source); calcitonin reduced this effect, but alendronate had no effect. OVX increased the expression of c-Fos (a neuronal marker of pain) in the thalamus; calcitonin strongly reversed this effect, and alendronate moderately reversed this effect. OVX also reduced SERT but increased 5-HT1A receptor expression and activity; calcitonin aggravated this effect, but alendronate had no effect on recovery of SERT/5-HT1A activity and expression.

Conclusions

Our study of a rat model of osteoporosis suggests that OVX-induced enhancement of the serotonergic system may protect against hyperalgesia. However, the anti-nociceptive effects of calcitonin in osteoporosis may be mediated by decreased neural SERT activity and increased activation of 5-HT1 receptors in the thalamus.
Literature
1.
Diab DL, Watts NB (2013) Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 20:501–509CrossRefPubMed
2.
Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170CrossRefPubMed
3.
Karsdal MA, Henriksen K, Arnold M, Christiansen C (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22:137–144CrossRefPubMed
4.
Takayama B, Kikuchi S, Konno S, Sekiguchi M (2008) An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats. BMC Musculoskelet Disord 9:164CrossRefPubMedPubMedCentral
5.
Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H (2011) Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int 22:2735–2742CrossRefPubMed
6.
Fujita T, Ohue M, Nakajima M, Fujii Y, Miyauchi A, Takagi Y (2011) Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. J Bone Miner Metab 29:588–597CrossRefPubMed
7.
8.
9.
Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D (2012) Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 23:17–38CrossRefPubMed
10.
Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281–1290CrossRefPubMed
11.
Gobelet C, Meier JL, Schaffner W, Bischof-Delaloye A, Gerster JC, Burckhardt P (1986) Calcitonin and reflex sympathetic dystrophy syndrome. Clin Rheumatol 5:382–388CrossRefPubMed
12.
Hamamci N, Dursun E, Ural C, Cakci A (1996) Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Br J Clin Pract 50:373–375PubMed
13.
Matayoshi S, Shimodozono M, Hirata Y, Ueda T, Horio S, Kawahira K (2009) Use of calcitonin to prevent complex regional pain syndrome type I in severe hemiplegic patients after stroke. Disabil Rehabil 31:1773–1779CrossRefPubMed
14.
Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ (2001) Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manag 21:511–526CrossRef
15.
Quatraro A, Minei A, De Rosa N, Giugliano D (1992) Calcitonin in painful diabetic neuropathy. Lancet 339:746–747CrossRefPubMed
16.
Visser EJ, Kwei PL (2006) Salmon calcitonin in the treatment of post herpetic neuralgia. Anaesth Intensive Care 34:668–671PubMed
17.
18.
19.
20.
Guidobono F, Netti C, Sibilia V, Olgiati VR, Pecile A (1985) Role of catecholamines in calcitonin-induced analgesia. Pharmacology 31:342–348CrossRefPubMed
21.
Maeda Y, Yamada K, Hasegawa T, Nabeshima T (1995) Neuronal mechanism of the inhibitory effect of calcitonin on N-methyl-D-aspartate-induced aversive behavior. Eur J Pharmacol 275:163–170CrossRefPubMed
22.
Meisenberg G, Simmons WH (1983) Minireview. Peptides and the blood–brain barrier. Life Sci 32:2611–23CrossRefPubMed
23.
24.
Sibilia VF, Pagani N, Lattuada D, Rapetti F, Guidobono NC (2000) Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. Brain Res 854:79–84CrossRefPubMed
25.
26.
Viguier F, Michot B, Hamon M, Bourgoin S (2013) Multiple roles of serotonin in pain control mechanisms—implications of 5-HT(7) and other 5-HT receptor types. Eur J Pharmacol 716:8–16CrossRefPubMed
27.
28.
Martin VT (2009) Ovarian hormones and pain response: a review of clinical and basic science studies. Gend Med 6(Suppl 2):168–192CrossRefPubMed
29.
Ito A, Takeda M, Yoshimura T, Komatsu T, Ohno T, Kuriyama H, Matsuda A, Yoshimura M (2012) Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors. Mol Pain 8:42CrossRefPubMedPubMedCentral
30.
Kharode YP, Sharp MC, Bodine PV (2008) Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol 455:111–124CrossRefPubMed
31.
Zheng XF, Li B, Zhang YH, Yang YH, Meng XY, Jiang SD, Jiang LS (2013) Blockade of substance P receptor attenuates osteoporotic pain, but not bone loss, in ovariectomized mice. Menopause 20:1074–1083CrossRefPubMed
32.
Egermann M, Goldhahn J, Schneider E (2005) Animal models for fracture treatment in osteoporosis. Osteoporos Int 16(Suppl 2):S129–138CrossRefPubMed
33.
Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA (2008) The laboratory rat as an animal model for osteoporosis research. Comp Med 58:424–430PubMedPubMedCentral
34.
Kuo YJ, Tsuang FY, Sun JS, Lin CH, Chen CH, Li JY, Huang YC, Chen WY, Yeh CB, Shyu JF (2012) Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis. PLoS One 7:e40272CrossRefPubMedPubMedCentral
35.
Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283–8CrossRefPubMed
36.
Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R (1993) The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain 54:43–50CrossRefPubMed
37.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77–88CrossRefPubMed
38.
Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, Burlington, MA, USA, p 208
39.
Muller R, Van Campenhout H, Van Damme B, Van Der Perre G, Dequeker J, Hildebrand T, Ruegsegger P (1998) Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 23:59–66CrossRefPubMed
40.
Abate G, Taormina F, Brillante C, Fraccalaglio L (1994) The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis. Minerva Med 85:253–259PubMed
41.
Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367:2416–2425CrossRefPubMedPubMedCentral
42.
Hirsch PF, Lester GE, Talmage RV (2001) Calcitonin, an enigmatic hormone: does it have a function? J Musculoskelet Nueronal Interact 1:299–305
43.
Overman RA, Borse M, Gourlay ML (2013) Salmon calcitonin use and associated cancer risk. Ann Pharmacother 47:1675–1684CrossRefPubMed
44.
Purdue BW, Tilakaratne N, Sexton PM (2002) Molecular pharmacology of the calcitonin receptor. Recept Channels 8:243–255CrossRefPubMed
Metadata
Title
Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity
Authors
C.-B. Yeh
S.-J. Weng
K.-W. Chang
J. Y.-H. Chan
S.-M. Huang
T.-H. Chu
N.-K. Wei
H.-S. Ma
J.-T. Cheng
K.-H. Ma
T.-H. Chen
J.-F. Shyu
Publication date
01-11-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 11/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3652-1

Other articles of this Issue 11/2016

Osteoporosis International 11/2016 Go to the issue

Letter

Response to comments by Moran et al. on: The effect of prolonged breast-feeding on the development of postmenopausal osteoporosis in population with insufficient calcium intake and vitamin D level

Review

Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis

Review

Considerations concerning the definition of sarcopenia

Original Article

Systemic markers of microvascular disease and bone mineral density in older adults

Original Article

Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study

Original Article

Association of 3q13.32 variants with hip trochanter and intertrochanter bone mineral density identified by a genome-wide association study